Gamida Cell Announces Dosing of 1st Patient in Phase 1/2 Study of GDA-201
Researchers have shown that ratio of nicotinic acid (NA) to nicotinamide (NAM) in cell cultures significantly increases with the presence of live microorganisms within 24 hours, acting as a useful biomarker for the detection of early-stage microbial contamination in cell therapies.
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced data evaluating the mechanism of action of nicotinamide (NAM)-enabled NK cells, demonstrating enhanced homing, cytotoxicity and tumor reduction by GDA-201, the lead candidate in its NAM-enabled NK cell therapy pipeline. The data will be presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021) taking place in Washington, DC, and virtually November 10-14, 2021.
LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a first-of-its-kind clinical study published in the peer-reviewed journal, Movement Disorders, conducted by Michèl A.A.P. Willemsen MD, PhD of Radboud University Medical Center. The study investigated ChromaDex’s proprietary Niagen® ingredient (patented nicotinamide riboside, or “NR”) in patients with ataxia-telangiectasia (AT), a rare, inherited neurodegenerative disorder characterized by premature aging, cerebellar degeneration, immunodeficiency, and cancer predisposition. The study found that supplementation with NR improved ataxia scores and increased immunoglobulins, or antibodies, in the immune-compromised patients. In addition to the findings, this was the first published clinical NR trial to include participants under the age of 18, examining the potential impact NR might have in children with AT.
Gamida Cell Announces Updated Data from Phase 1 Study of GDA-201
Enforcement Report - Week of August 14, 2019
Enforcement Report - Week of June 19, 2019
Enforcement Report for Week of February 20, 2019
Tru Niagen (Nicotinamide riboside) : ChromaDex vs. Elysium Health
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products announced today that it has signed a new, exclusive patent license and research agreement with The Scripps Research Institute (TSRI), gaining access to groundbreaking, pre-clinical discoveries by Dr. Brunie Felding.